Related Experiment Videos
Summary
This study investigated the pharmacokinetics of Damvar (delta-(2-amino-6-hydroxy-3,4-dihydro-4-oxo-5-pyrimidinyl) valeric acid) in cancer patients. Damvar exhibits slow absorption and primarily relies on metabolic functions, not renal clearance, for elimination.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Metabolism
Background:
- Understanding drug pharmacokinetics is crucial for optimizing therapeutic efficacy and safety.
- Neoplastic diseases can significantly alter drug metabolism and elimination pathways.
Purpose of the Study:
- To characterize the pharmacokinetic profile of granulated Damvar following a single oral dose in subjects with neoplastic disease.
- To evaluate the absorption, distribution, elimination, and half-life of Damvar.
Main Methods:
- A single oral dose of 1000 mg granulated Damvar was administered to 10 subjects with neoplastic disease.
- Serum concentrations of Damvar were monitored over time.
- Pharmacokinetic parameters were analyzed using a two-compartmental model.
- Urinary excretion and renal clearance of Damvar were assessed over 24 hours.
Main Results:
- Damvar absorption from the digestive tract was slow, with peak serum levels of 13.5 µg/mL reached at 3 hours.
- The drug followed a two-compartmental pharmacokinetic model with a biological half-life of 9.72 ± 0.84 hours.
- Urinary elimination was minimal (3.1% of the dose in 24 hours) with low renal clearance (0.05 mL/s).
Conclusions:
- The kidneys play a minor role in Damvar elimination.
- Therapeutic strategies involving Damvar should consider the patient's metabolic function due to limited renal excretion.
- Further investigation into Damvar's disposition in patients with altered metabolic functions is warranted.